Chemistry:Pyr-T
From HandWiki
| |
| Names | |
|---|---|
| Preferred IUPAC name
3-[2-(Pyrrolidin-1-yl)ethyl]-1H-indole | |
| Other names
N,N-Tetramethylenetryptamine
| |
| Identifiers | |
3D model (JSmol)
|
|
| ChemSpider | |
PubChem CID
|
|
| UNII | |
| |
| |
| Properties | |
| C14H18N2 | |
| Molar mass | 214.312 g·mol−1 |
| Melting point | 193 to 194 °C (379 to 381 °F; 466 to 467 K) (HCl salt.) |
| Boiling point | 170 to 180 °C (338 to 356 °F; 443 to 453 K) (Freebase at 0.05mm/Hg.) |
| log P | 2.74410 |
| Vapor pressure | 1.02x10−5mmHg |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
 verify (what is   ?)
| |
| Infobox references | |
Tracking categories (test):
Pyr-T (N,N-tetramethylenetryptamine) is a lesser-known, possible psychedelic drug. Pyr-T was first characterized by S. Mitzal.[1] Toxicity testing was later performed by Hunt and Brimblecombe, and although a lethal dosage was found in rats, a value is not given.[2] In the book TiHKAL (Tryptamines I Have Known and Loved), neither the dosage nor the duration are reported.[3][4]
Pyr-T produces few to no effects in humans, but some behavioral changes were observed in animal tests.[2] Very little data exists about the pharmacological properties, metabolism, and toxicity of pyr-T.
See also
- 4-HO-pyr-T
- 5-MeO-pyr-T
- MPMI
- SN-22
- Tryptamine
- Psychedelics, dissociatives and deliriants
References
- ↑ Mitzal, S. (1962). "N/A". Dissertationes Pharm. 14: 305.
- ↑ 2.0 2.1 Hunt, R. R.; Brimblecombe, R. W. (July 1967). "Synthesis and Biological Activity of Some Ring-Substituted Tryptamines". Journal of Medicinal Chemistry 10 (4): 646–648. doi:10.1021/jm00316a027. PMID 4962512.
- ↑ Shulgin, Alexander; Shulgin, Ann (1997). TiHKAL, The Continuation (1st ed.). Berkeley, CA, USA: Transform Press. pp. 577–578. ISBN 0-9630096-9-9. https://erowid.org/library/books_online/tihkal/tihkal52.shtml. Retrieved 7 April 2018.
- ↑ Krasowski MD, Ekins S. Using cheminformatics to predict cross reactivity of “designer drugs” to their currently available immunoassays. J Cheminform 6, 22 (2014). doi:10.1186/1758-2946-6-22
 |  |
